JNJ vs RKT.L
JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges. RKT.L: A global leader in consumer health, hygiene, and nutrition products with a portfolio of trusted, household-name brands.
Side-by-side fundamentals
| Metric | JNJ | RKT.L | Edge |
|---|---|---|---|
| Price as of 2026-08-05 close | $257.59 | £52.80 | |
| Market cap as of 2026-08-06 | $620.8B | n/a | |
| P/E as of 2026-08-06 | 29.51 | n/a | |
| PEG as of 2026-08-06 | 3.39 | n/a | |
| Net margin as of 2026-08-06 | +21.5% | n/a | |
| Gross margin as of 2026-08-06 | +68.0% | n/a | |
| Operating margin as of 2026-08-06 | +25.7% | n/a | |
| ROE as of 2026-08-06 | +25.7% | n/a | |
| ROA as of 2026-08-06 | +10.6% | n/a | |
| Debt / equity as of 2026-08-06 | 0.58 | n/a | |
| Revenue growth (YoY) as of 2026-08-06 | +8.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +6.2% | n/a | |
| Dividend yield as of 2026-08-06 | +2.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-06 | 0.20 | n/a | |
| 1-year return as of 2026-08-05 close | +50.9% | -5.2% | JNJ higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-05.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.